GLP-1 truths for the woman on Ozempic.

Roughly 12% of American adults have now used a GLP-1 weight-loss medication (Ozempic, Wegovy, Mounjaro, Zepbound). For women between 45 and 65, the rate is higher — closer to 18%. There's a real chance this letter applies to you or to someone close to you.

The drugs work. The 14.9% (semaglutide) to 20.9% (tirzepatide) weight loss numbers from the STEP-1 and SURMOUNT-1 trials are real. For post-menopausal weight redistribution specifically, the data is even better than for general adult populations because the visceral fat pattern (covered in letter #2) is exactly what these drugs hit hardest.

But there are things you should know that the prescribing telehealth clinic may not have told you.

What the drugs do well

• Visceral fat loss. GLP-1s preferentially reduce abdominal/visceral fat — exactly the post-menopausal pattern.
• Glucose control. Improves insulin sensitivity dramatically. If you have any pre-diabetes signal (HbA1c 5.7-6.4), this resolves on GLP-1 for most users.
• Cardiovascular outcomes. SELECT trial, 2023 NEJM — semaglutide reduced major adverse cardiovascular events by 20% in overweight adults without diabetes. The drug isn't just a weight drug; it's a cardiovascular drug.
• Food noise reduction. Most users report a dramatic reduction in the constant background thinking about food. This is the part that surprises people most — it's not willpower making the eating easier; the cognitive load is just gone.

What the drugs do that you need to manage

1. Muscle loss is real and substantial. Without intervention, weight loss on GLP-1s is roughly 60% fat / 40% lean mass. That lean loss includes muscle — and at 50+, the muscle you lose is harder to rebuild than at 30.

The fix is non-negotiable: protein floor + resistance training. Get 0.8g protein per pound bodyweight every day across 3-4 meals. Lift heavy 2-3x per week (letter #12). Without this, you'll be smaller but more sarcopenic — and likely to regain mostly as fat when you stop the drug.

This is the single most underemphasized thing in GLP-1 prescribing.

2. Bone density may decrease. Less data here than the muscle question, but emerging evidence suggests modest bone loss during rapid weight loss on GLP-1s, especially in post-menopausal women. Mitigations: weight-bearing exercise, adequate calcium (1,200mg/day) and vitamin D (2,000 IU/day), and the resistance training already on the list.

3. The "Ozempic face" is real and is just rapid fat loss. Subcutaneous facial fat decreases proportionally with overall fat loss. There's no special protocol for it; the face follows the body. Some users find aesthetic procedures helpful; many adjust without intervention.

4. The drug is most effective at higher doses, which means dose-titration matters. Most clinics start at low doses to manage nausea, then titrate up over months. Don't stay at a sub-therapeutic dose because the side effects were uncomfortable; the side effects usually attenuate.

5. Gallstone risk increases at higher doses. If you have a history of gallbladder issues or rapid weight loss has caused gallstones in the past, talk to your prescriber about a slower titration.

What happens when you stop

This is the hardest conversation in GLP-1 medicine.

STEP-4 extension trial showed that participants who stopped semaglutide regained roughly two-thirds of their lost weight within one year. The mechanism: the drug suppresses appetite by acting on GLP-1 receptors. Stop the drug, the suppression stops, the appetite returns.

This means GLP-1s are more accurately framed as chronic-use medications like statins or blood pressure drugs — not "weight loss medications" used short-term.

If you started thinking you'd be on it for 6 months, recalibrate. Most users either:

• Stay on long-term (often at lower maintenance dose),
• Cycle off slowly with intensive lifestyle support and accept some regain, or
• Stop entirely and accept full regain.

There isn't a clean "off ramp" the same way there's a clean off-ramp from antibiotics. This is okay if you go in knowing it.

The maintenance protocol for post-GLP-1

If and when you taper or stop:

1. Maintain the protein floor. 0.8g/lb continues.
2. Maintain resistance training 2-3x/week. This is what preserves the lean mass.
3. Maintain a slightly lower calorie set point than your pre-drug eating. Most people's appetite returns to baseline; their body needs less than baseline after the loss.
4. Annual bloodwork to watch for any rebound metabolic markers (HbA1c, lipid panel, fasting insulin).
5. Consider an HRT conversation if you're peri-/post-menopausal. Estrogen plus GLP-1 (or post-GLP-1) appears to produce better body composition outcomes than either alone in observational data. The randomized trial data is forthcoming.

On the supply and cost question

Brand-name semaglutide and tirzepatide are expensive ($1,000-$1,500/month) and intermittently out of stock. Compounded versions are 50-70% less and more available. Quality varies. If you go compounded:

• Use a 503A or 503B pharmacy with NABP accreditation
• Ask about USP <797> sterile compounding compliance
• Ask about per-batch testing for purity and potency

The 2024-2025 FDA warnings about compounded semaglutide are worth reading. Most compounded product is fine. Some isn't.

Next week: BPC-157 and healing peptides — the research-grey category you've probably heard about.

Alexander After Forty Feel Reader-funded. Research-led. No supplement-brand sponsorships.